Version May 2024
| Agent | Brand name | Dosing |
| Arformoterol | Brovana (United States) | Solution for nebulization: Inhale contents of 1 vial (15 mcg/2 mL) twice daily via standard jet nebulizer¶ |
| FormoterolΔ | Perforomist (United States) | Solution for nebulization: Inhale contents of 1 vial (20 mcg/2 mL) twice daily via standard jet nebulizer¶ |
| Foradil◊ | DPI:§ Inhale contents of 1 capsule (12 mcg/capsule) twice daily¥ | |
| Oxeze Turbuhaler (Canada: 6 mcg/inhalation and 12 mcg/inhalation)‡ | DPI: 1 to 2 inhalations (12 to 24 mcg total dose) twice daily | |
| Indacaterol† | Onbrez Breezhaler (EU, UK, other areas) | DPI:§ Inhale contents of 1 capsule (150 or 300 mcg/capsule) once daily |
| Olodaterol | Striverdi Respimat (United States) | SMI: 2 inhalations (2.5 mcg/actuation) once daily |
| Salmeterol | Serevent Diskus (United States/Canada) | DPI:§ 1 inhalation (50 mcg/actuation) twice daily |
COPD: chronic obstructive pulmonary disease; DPI: dry powder inhaler; LABA: long-acting beta-agonist; SMI: soft mist inhaler.
* Vilanterol is not available as a single agent. Refer to relevant clinical topics and Lexicomp drug monographs included within UpToDate for information about combination inhalers containing vilanterol with a long-acting muscarinic antagonist and/or inhaled glucocorticoid.
¶ Data about mixing nebulized medications are limited; refer to the UpToDate topic on delivery of inhaled medications, table on mixing nebulized medications, and Lexicomp drug information monographs included within UpToDate.
Δ Formoterol is not available as a single agent inhaler in the United States. Refer to relevant clinical topics and Lexicomp drug monographs included within UpToDate for information about combination inhalers containing formoterol with a long-acting muscarinic antagonist and/or inhaled glucocorticoid.
◊ No longer available in the United States, but may be available elsewhere.
§ DPIs contain lactose and may contain milk protein, which may put patients with milk protein allergy at risk.
¥ In countries outside the United States, formoterol doses of 48 mcg/day (24 mcg twice daily) are approved. Refer to local product information.
‡ Oxeze Turbuhaler is approved in Canada for use in asthma but not COPD.
† Indacaterol is no longer marketed as a single ingredient inhalation in United States or Canada. An indacaterol DPI (Onbrez Breezhaler) is approved in UK, EU and some other areas; efficacy and dose-related safety is discussed in UpToDate content on initial management of COPD.آیا می خواهید مدیلیب را به صفحه اصلی خود اضافه کنید؟
